Allergy Therapeutics PLC (AIM:AGY) has hailed the results from a study that it said demonstrated a “clear treatment effect” from its short-course immunotherapy targeting grass pollen allergies.
The exploratory field trial was designed to evaluate the efficacy and safety of Grass MATA MPL.
The primary aim was achieved with the jab providing a “clinically relevant improvement” across both active treatment groups compared to placebo with no medicinal value.
Specifically, there was a 29.1% improvement in the symptoms for those on the six-week course, which rose to 36.8% for those receiving treatment over 14 weeks. Quality of life was also enhanced, the data showed. The drug was well tolerated.
In all, 119 people took part in the evaluation at sites in the US and Germany. Scientists will evaluate the data further.
The assessment of Grass MATA MPL paves the way for Allergy’s phase III clinical trial of the grass pollen treatment in the second half of next year.
“Grass pollen is one of the most common causes of seasonal allergic rhinitis in the western world,” said Manuel Llobet, the company’s chief executive.
“Debilitating symptoms can affect so many aspects of life and new treatment options are needed.”